ABP 321
Alternative Names: ABP-321Latest Information Update: 07 Jul 2023
At a glance
- Originator Abpro Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 30 Jun 2023 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) (Abpro Therapeutics pipeline, June 2023)